135 related articles for article (PubMed ID: 3065101)
1. Bumetanide, spironolactone and a combination of the two, in the treatment of ascites due to liver disease. A prospective, controlled, randomized trial.
Sarin SK; Sachdev G; Mishra SP; Sundaram KR; Shrivastwa A; Talukdar V; Broor SL
Digestion; 1988; 41(2):101-7. PubMed ID: 3065101
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system.
Pérez-Ayuso RM; Arroyo V; Planas R; Gaya J; Bory F; Rimola A; Rivera F; Rodés J
Gastroenterology; 1983 May; 84(5 Pt 1):961-8. PubMed ID: 6339312
[TBL] [Abstract][Full Text] [Related]
3. A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients.
Gatta A; Angeli P; Caregaro L; Menon F; Sacerdoti D; Merkel C
Hepatology; 1991 Aug; 14(2):231-6. PubMed ID: 1860680
[TBL] [Abstract][Full Text] [Related]
4. Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo.
Fernández-Esparrach G; Guevara M; Sort P; Pardo A; Jiménez W; Ginès P; Planas R; Lebrec D; Geuvel A; Elewaut A; Adler M; Arroyo V
J Hepatol; 1997 Mar; 26(3):614-20. PubMed ID: 9075669
[TBL] [Abstract][Full Text] [Related]
5. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety.
Santos J; Planas R; Pardo A; Durández R; Cabré E; Morillas RM; Granada ML; Jiménez JA; Quintero E; Gassull MA
J Hepatol; 2003 Aug; 39(2):187-92. PubMed ID: 12873814
[TBL] [Abstract][Full Text] [Related]
6. Bumetanide in the treatment of hepatic ascites.
Ring-Larsen H
Postgrad Med J; 1975; 51 Suppl 6():77-81. PubMed ID: 1105536
[No Abstract] [Full Text] [Related]
7. Liver cirrhosis with ascites: pathogenesis of resistance to diuretics and long-term efficacy and safety of torasemide.
Knauf H; Mutschler E
Cardiology; 1994; 84 Suppl 2():87-98. PubMed ID: 7954550
[TBL] [Abstract][Full Text] [Related]
8. Predictive factors influencing the therapeutic response to diuretic treatment of ascites in nonazotemic cirrhotic patients.
Ljubicić N; Kujundzić M; Banić M; Vrkljan M
Scand J Gastroenterol; 1998 Apr; 33(4):441-7. PubMed ID: 9605268
[TBL] [Abstract][Full Text] [Related]
9. The diuretic effect of muzolimine (Bay g 2821) on hepatogenic ascites.
Heinrich F; Loew D; Dýcka J
Curr Med Res Opin; 1976-1977; 4(10):706-15. PubMed ID: 800972
[TBL] [Abstract][Full Text] [Related]
10. Use of diuretics in the treatment of cirrhotic ascites.
Boyer TD; Warnock DG
Gastroenterology; 1983 May; 84(5 Pt 1):1051-5. PubMed ID: 6832557
[No Abstract] [Full Text] [Related]
11. An optimal diuretic regimen for cirrhotic ascites. A controlled trial evaluating safety and efficacy of spironolactone and furosemide.
Fuller RK; Khambatta PB; Gobezie GC
JAMA; 1977 Mar; 237(10):972-5. PubMed ID: 319263
[TBL] [Abstract][Full Text] [Related]
12. Torasemide versus furosemide in cirrhosis: a long-term, double-blind, randomized clinical study.
Fiaccadori F; Pedretti G; Pasetti G; Pizzaferri P; Elia G
Clin Investig; 1993 Jul; 71(7):579-84. PubMed ID: 8374255
[TBL] [Abstract][Full Text] [Related]
13. Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial.
Descos L; Gauthier A; Levy VG; Michel H; Quinton A; Rueff B; Fermanian J; Fombonne E; Durbec JP
Hepatogastroenterology; 1983 Feb; 30(1):15-20. PubMed ID: 6339343
[TBL] [Abstract][Full Text] [Related]
14. Use of piretanide, a new loop diuretic, in cirrhosis with ascites: relationship between the diuretic response and the plasma aldosterone level.
Arroyo V; Bosch J; Casamitjana R; Cabrera J; Rivera F; Rodés J
Gut; 1980 Oct; 21(10):855-9. PubMed ID: 7439805
[TBL] [Abstract][Full Text] [Related]
15. The effects of treatment with octreotide, diuretics, or both on portal hemodynamics in nonazotemic cirrhotic patients with ascites.
Kalambokis G; Economou M; Kosta P; Papadimitriou K; Tsianos EV
J Clin Gastroenterol; 2006 Apr; 40(4):342-6. PubMed ID: 16633107
[TBL] [Abstract][Full Text] [Related]
16. The effects of a single, intravenous dose of bumetanide versus furosemide in patients with ascites and edema due to alcoholic liver disease.
Koff RS
J Clin Pharmacol; 1981; 21(11):706-11. PubMed ID: 7040497
[TBL] [Abstract][Full Text] [Related]
17. Bumetanide in refractory ascites of cirrhosis of the liver: a comparison with furosemide.
Iber FL; Baum RA
J Clin Pharmacol; 1981; 21(11):697-700. PubMed ID: 7338581
[TBL] [Abstract][Full Text] [Related]
18. Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system.
Lenaerts A; Codden T; Meunier JC; Henry JP; Ligny G
Hepatology; 2006 Oct; 44(4):844-9. PubMed ID: 17006921
[TBL] [Abstract][Full Text] [Related]
19. [Biological factors influencing response to diuretics in patients with cirrhosis and ascites].
Lenaerts A; Codden T; Henry JP; Van Cauter J; Meunier JC; Ligny G
Gastroenterol Clin Biol; 2001 Mar; 25(3):268-72. PubMed ID: 11395674
[TBL] [Abstract][Full Text] [Related]
20. [Bumetanide therapy of cirrhotic ascites. Comparison of different doses and modes of administration].
Saffiotti O; Balzano A; Rinaldi M; Savarese M; Sito M; Del Vecchio-Blanco C
Clin Ter; 1983 May; 105(4):281-8. PubMed ID: 6872470
[No Abstract] [Full Text] [Related]
[Next] [New Search]
